New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
19:12 EDTSGMOSangamo BioSciences upgraded to Overweight from Underweight at Piper Jaffray
Piper Jaffray upgraded Sangamo BioSciences two notches to Overweight from Underweight and raised its price target for shares to $10 from $4 after assuming coverage of the stock. Piper says the company has a broad gene therapy platform with increasing visibility.
News For SGMO From The Last 14 Days
Check below for free stories on SGMO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 23, 2014
10:02 EDTSGMOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:03 EDTSGMOSangamo initiated with a Buy at Jefferies
Subscribe for More Information
September 15, 2014
07:27 EDTSGMOIBC Life Sciences to hold a conference
Subscribe for More Information
September 10, 2014
07:06 EDTSGMOSangamo plans to submit IND application for hemophilia B in 2Q15
Sangamo BioSciences (SGMO) plans to submit an Investigational New Drug application for the treatment of hemophilia B in Q2 2015. This program, partnered with Shire (SHPG), is the first therapeutic application of Sangamo's zinc finger nuclease-mediated In Vivo Protein Replacement Platform. Sangamo is developing the IVPRP as a generally applicable strategy to provide a one-time, permanent genetic cure for monogenic diseases that are currently managed by protein replacement therapy, which involves costly repeat infusions over the lifetime of the patient.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use